MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

Now in its third year, the trial is led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the University of Pennsylvania. It is funded by the Coronavirus ...

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...

MaxCyte will host a conference call today, March 11, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived ...

A novel acoustofluidics method enhances intracellular nanoparticle delivery, improving biophysical research and therapeutic ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle delivery. This method ...

This study shows that engineered E. coli Nissle 1917 producing indole-3-acetic acid (IAA), an AhR agonist, modulate the tumor ...

Cell growth usually refers to cell proliferation, the increase in cell numbers that occurs through repeated cell division. Cell growth can also refer to the enlargement of cell volume, which can ...

Mayo Clinic's Precision Mouse Engineering Core in Minnesota makes embryonic stem (ES) cell-based gene-targeted mice available to researchers.

Your body is made of cells -- trillions of them. Cells are the basic building blocks of people and all other living things. Researchers study them to learn more about health and diseases.